Rib-X Pharmaceuticals Receives $20,000,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4000817f-b5f4-451a-8605-2df25c22495c&Preview=1 -
Date
1/11/2011 -
Company Name
Rib-X Pharmaceuticals -
Mailing Address
300 George Street New Haven, CT 06511 -
Company Description
Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. -
Website
http://www.rib-x.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation. We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our R?-04 program in early 2011. -
M&A Terms
-
Venture Investor
Warburg Pincus -
Venture Investor
Undisclosed
